The Swedish Medicines Agency has previously rejected Moderna's application to test the vaccine. The vaccine is an mRNA vaccine, and Moderna is seeking full approval to offer the vaccine to adults aged 50 to 64.

Moderna shares surge after U.S. FDA to consider its flu shot
Pharmaceutical company Moderna surged 8 percent in U.S. premarket trading after the announcement that the U.S. FDA will consider its flu shot.
Advertisement







What do you think?